APA (7th ed.) Citation

Parisi, A., Parisi, A., Giampieri, R., Mammarella, A., Felicetti, C., Salvatore, L., . . . Ghidini, M. (2022, August). Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis. Frontiers in Oncology.

Chicago Style (17th ed.) Citation

Parisi, Alessandro, et al. "Primary Versus Secondary Antiemetic Prophylaxis with NK1 Receptor Antagonists in Patients Affected by Gastrointestinal Malignancies and Treated with a Doublet or Triplet Combination Regimen Including Oxaliplatin And/or Irinotecan Plus Fluoropyrimidines: A Propensity Score Matched Analysis." Frontiers in Oncology Aug. 2022.

MLA (9th ed.) Citation

Parisi, Alessandro, et al. "Primary Versus Secondary Antiemetic Prophylaxis with NK1 Receptor Antagonists in Patients Affected by Gastrointestinal Malignancies and Treated with a Doublet or Triplet Combination Regimen Including Oxaliplatin And/or Irinotecan Plus Fluoropyrimidines: A Propensity Score Matched Analysis." Frontiers in Oncology, Aug. 2022.